Wednesday, 22 September 2010

U-turn as NICE approves Sutent kidney cancer drug



A U-turn by the drugs watchdog NICE means kidney cancer patients in England could soon have their lives extended by months through the use of Sutent, a previously rejected course of treatment

No comments:

Post a Comment